While biologics targeting IL-17 and TNF have failed to show benefit in unselected asthma populations (28, 29); perhaps only a subset of patients – e.g. those prone to severe RV-triggered exacerbations – may derive benefit from these treatment strategies. The gene discussed is TNF; the disease is asthma.